Featured Research

from universities, journals, and other organizations

Risk of recurrence low in smallest HER2+ breast cancer tumors

Date:
June 2, 2014
Source:
Kaiser Permanente
Summary:
Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a study. for patients with the smallest HER2+ tumors (0.5 centimeters or less) who did not receive treatment with the antibody trastuzumab or chemotherapy, the chance of surviving five years without a distant recurrence (cancer that spreads outside the breast to other organs) was 99 percent. For patients with the next size tumor (0.6 to 1 centimeter) the chance of surviving five years without a distant recurrence was 97 percent.

Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology.

Related Articles


Researchers reviewed 16,975 cases of breast cancer diagnosed in Kaiser Permanente patients between 2000 and 2006. They found that for patients with the smallest HER2+ tumors (0.5 centimeters or less) who did not receive treatment with the antibody trastuzumab or chemotherapy, the chance of surviving five years without a distant recurrence (cancer that spreads outside the breast to other organs) was 99 percent. A distant recurrence is considered to be more threatening than a local recurrence in the breast.

For patients with the next size tumor (0.6 to 1 centimeter) the chance of surviving five years without a distant recurrence was 97 percent.

"Our results suggest that trastuzumab therapy may not be needed for patients with HER2+ tumors that are 0.5 centimeters in size or smaller, but should be considered for patients with larger tumors, with stronger consideration as the tumor size nears 1 centimeter," said lead author Lou Fehrenbacher, MD, medical director of Kaiser Permanente Oncology Clinical Trials and oncologist with Kaiser Permanente Vallejo Medical Center. "This is the first large study to demonstrate that the smallest lymph node-negative HER2+ breast cancers have a very low chance of returning."

Typical treatments for small, lymph-node-negative HER2+ tumors include surgery to remove the tumor and radiation therapy, although trastuzumab and chemotherapy are also frequently used to treat patients. HER2+ breast cancer, a subtype that accounts for between 15 and 20 percent of all cases of breast cancer in the United States, has been shown to respond well to trastuzumab. However trastuzumab can lead to heart failure in some women, particularly those who are older and who have other disease conditions.

Unlike larger tumors where distant recurrences are more common, the study found that the risk of local and distant recurrences was similar for these small HER2+ breast cancer tumors.


Story Source:

The above story is based on materials provided by Kaiser Permanente. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. Fehrenbacher, A. M. Capra, C. P. Quesenberry, R. Fulton, P. Shiraz, L. A. Habel. Distant Invasive Breast Cancer Recurrence Risk in Human Epidermal Growth Factor Receptor 2-Positive T1a and T1b Node-Negative Localized Breast Cancer Diagnosed From 2000 to 2006: A Cohort From an Integrated Health Care Delivery System. Journal of Clinical Oncology, 2014; DOI: 10.1200/JCO.2013.52.0858

Cite This Page:

Kaiser Permanente. "Risk of recurrence low in smallest HER2+ breast cancer tumors." ScienceDaily. ScienceDaily, 2 June 2014. <www.sciencedaily.com/releases/2014/06/140602162658.htm>.
Kaiser Permanente. (2014, June 2). Risk of recurrence low in smallest HER2+ breast cancer tumors. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2014/06/140602162658.htm
Kaiser Permanente. "Risk of recurrence low in smallest HER2+ breast cancer tumors." ScienceDaily. www.sciencedaily.com/releases/2014/06/140602162658.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins